By modifying T cells to express receptors that selectively target tumor-associated antigens (TAAs) such Epidermal Growth Factor Receptor Variant III (EGFRvIII), Interleukin-13 Receptor Alpha 2 (IL-13Rα2) and Human Epidermal Growth Factor Receptor 2 (HER2), CAR-T therapy seeks to overcome these obstacles 38. This evidence concerns the gene ERBB2 and neoplasm.